Condition
Relapsed/Refractory Diffuse Large B-Cell Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Relapsed/Refractory Diffuse Large B-Cell Lymphoma clinical trials that are recruiting, at sites in 2 countries (most in China (3), Mexico (1)). By phase: Phase 3 (2), Phase 1/2 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest Relapsed/Refractory Diffuse Large B-Cell Lymphoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Low-dose epcoritamab with GemOx for relapsed/refractory DLBCL | Phase 2 | Monterrey, Nuevo León | Recruiting | Mar 5, 2026 |
| HMPL-760 with R‑GemOx versus placebo with R‑GemOx for relapsed or refractory diffuse large B‑cell lymphoma | Phase 3 | Shanghai, Shanghai Municipality and 50 other locations | Recruiting | Feb 13, 2026 |
| Evaluating early second infusion of CAR T-cell therapy for lymphoma | Phase 1/2 | Guangzhou, Guangdong | Recruiting | Mar 30, 2025 |
| Comparing BEBT-908 with Rituximab to Standard Chemotherapy for Lymphoma | Phase 3 | Beijing, Beijing Municipality | Recruiting | Jan 24, 2025 |
All recruiting trials (4)
-
Low-dose epcoritamab with GemOx for relapsed/refractory DLBCL
This trial will test whether adding a low dose of epcoritamab to GemOx chemotherapy helps people with relapsed or refractory diffuse large B‑cell lymphoma who are eligible for autologous stem cell transplant.
-
HMPL-760 with R‑GemOx versus placebo with R‑GemOx for relapsed or refractory diffuse large B‑cell lymphoma
This trial will see if adding HMPL‑760 to R‑GemOx helps adults with relapsed or refractory diffuse large B‑cell lymphoma respond better or live longer than R‑GemOx plus placebo.
-
Evaluating early second infusion of CAR T-cell therapy for lymphoma
This study is testing if giving a second dose of CAR T-cell therapy earlier can help adults with tough-to-treat lymphoma feel better and live longer.
-
Comparing BEBT-908 with Rituximab to Standard Chemotherapy for Lymphoma
This study is testing whether a new treatment called BEBT-908 combined with rituximab can work better than standard chemotherapy for people with relapsed or hard-to-treat diffuse large B-cell lymphoma.
Related topics
Quick answers
How many Relapsed/Refractory Diffuse Large B-Cell Lymphoma clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (3 trials), Mexico (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 1/2: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.